In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according ...
May 31, 2014
0
0
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated ...
May 23, 2014
0
0
Patients with chronic lymphocytic leukemia (CLL) who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease.
Sep 11, 2018
0
7
Adoption of novel oral targeted therapies for treatment of chronic lymphocytic leukemia (CLL) could raise the treatment costs for the blood-system cancer in the U.S. by almost 600 percent. In their analysis in the Journal ...
Nov 21, 2016
0
0
Researchers at the University of California, San Diego School of Medicine report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined ...
Jan 2, 2014
0
0
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson ...
May 14, 2018
0
2
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur ...
Dec 12, 2012
0
0
Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Dec 9, 2012
0
0
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new ...
May 31, 2017
0
0
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
May 17, 2013
0
0
